drugset / Trial / NCT00760578
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Timeline
- Start
- 2008-09
- Primary completion
- 2009-01
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoglitazone | Small molecule | 90 mg | Oral |
| Subject | Mitoglitazone | Small molecule | 220 mg | Oral |
| Comparator | Pioglitazone | Small molecule | 45 mg | Oral |